Exclusive Licensing Agreement Reached Between Solstice Neurosciences, Inc. And DreamPharma Corporation For Cosmetic And Therapeutic Uses Of Myobloc(R)/NeuroBloc(R) In Korea

MALVERN, Pa., July 5 /PRNewswire/ -- Solstice Neurosciences, Inc. announced that it has reached an Exclusive License Agreement with DreamPharma Corporation of Seoul, Korea, to evaluate and develop cosmetic and therapeutic uses of Myobloc® (Botulinum Toxin Type B) Injectable Solution for a range of specialty biopharmaceutical products in Korean markets. The agreement includes the use of MYOBLOC in its injectable formulation as clostridium botulinum type B which was approved by the US Food and Drug Administration (FDA) in December 2000 and subsequently approved by the European Medicines Agency (EMEA) in January 2001.

This product, also known as NeuroBloc® in Europe, is approved for use in 26 EU countries and distributed in Austria, France, Germany, Ireland, Italy, Portugal, Spain, United Kingdom, and the United States.

DreamPharma Corporation, a subsidiary of the HANWHA Group in Seoul, Korea, is involved in priority research and development for aesthetic/cosmetic, metabolic (obesity) (Phase III clinical trials), urinary/dermatological (Phase II clinical trials), respiratory, and oncology products to supplement its existing product portfolio in these and other areas. The company has numerous business partners and network affiliations worldwide. For more information about DreamPharma, visit http://www.dreampharma.co.kr.

"This agreement provides Solstice with expanded opportunities in global markets as part of our long-term strategy to use MYOBLOC in therapeutic and cosmetic applications," said Shawn Patrick O'Brien, President & CEO of Solstice Neurosciences, Inc. Solstice was advised on this Exclusive License Agreement by Apeiron Partners LLC, Framingham, Massachusetts.

Ki-Joon Hong, President of DreamPharma Corporation said, "Our partnership with Solstice Neurosciences offers great potential to enhance our therapeutic interests and strengthen our growing portfolio of aesthetic products by adding MYOBLOC injectable solution."

About MYOBLOC

Myobloc® (Botulinum Toxin Type B) Injectable Solution was the first drug approved in the US to reduce the severity of abnormal head position and the neck pain associated with cervical dystonia. Treatment with MYOBLOC interrupts cholinergic transmission between nerves and the affected muscle, causing it to relax. The approval was based on randomized, multi-center, double-blind, placebo-controlled studies in adult patients. The product is also approved in Europe and Canada. MYOBLOC is provided as an injectable ready-to-use solution in three single-dose vial sizes of 0.5 mL (2500 U), 1.0 mL (5000 U), and 2.0 mL (10,000 U). MYOBLOC has a demonstrated shelf-life of four years.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, Myobloc® (Botulinum Toxin Type B) Injectable Solution 5,000U/mL, represents the only botulinum toxin type B currently available to physicians and patients worldwide. MYOBLOC is sold in the United States and approved in Canada. It is also sold and distributed in Europe as NeuroBloc®. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com

About Cervical Dystonia

Cervical Dystonia (CD), also known as spasmodic torticollis, is a condition that primarily affects the muscles of the head and neck (the cervical area of the spine). Cervical dystonia is the most common dystonia requiring referral to movement disorder clinics. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. Dystonia has an estimated prevalence of over 300,000 cases in North America. In general, there are three main approaches to the treatment of CD: oral medications, surgery, and toxin therapy.

Contacts:

United States Diane Murray, Director-Business Operations & Communications Phone: Toll-Free (866) 220-5042, or Direct (610) 864-1691 Email: diane.murray@solsticeneuro.com

Korea Soon-Jae, Park, Vice President-Business Development DreamPharma Corporation Phone: Direct: (82) 2 729 4108 Email: sjparkb@hanwha.co.kr

For more information about DreamPharma, visit http://www.dreampharma.co.kr.

MYOBLOC and NEUROBLOC are registered trademarks of Solstice Neurosciences, Inc.

Source: Solstice Neurosciences, Inc.